Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations Excluding Melanoma and Thyroid Cancer
Study Type: Treatment
Phase: II
NCTID: NCT02465060
Principal Investigator:
Benjamin Powers
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
Study Type: Treatment
Phase: III
NCTID: NCT07068074
Principal Investigator:
Luke Selby
A PHASE III STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Study Type: Treatment
Phase: III
NCTID: NCT06246916
Principal Investigator:
Gary Doolittle
A Randomized, Controlled, Multicenter, Phase III Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician?s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Study Type: Treatment
Phase: III
NCTID: NCT06264180
Principal Investigator:
Gary Doolittle
A Phase III Randomized Multicenter Open-Label Study of IDRX-42 versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors GIST after Imatinib Therapy StrateGIST 3
Study Type: Treatment
Phase: III
NCTID: NCT07218926
Principal Investigator:
Benjamin Powers
Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLAA02:01-positive Participants with Previously Treated Advanced Melanoma TEBE-AM
Study Type: Treatment
Phase: II/III
NCTID: NCT05549297
Principal Investigator:
Gary Doolittle